Arvid Harder

May 21, 2024 | medrxiv.org | Joëlle A Pasman |Jacob Bergstedt |Arvid Harder |Ying Xiong

PFS is consultant and shareholder at Neumora Therapeutics. No other authors report potential conflicts of interest. This work was supported by the US National Institutes of Mental Health (R01MH123724), the European Unions Horizon 2020 Research and Innovation Programme (CoMorMent project; Grant #847776) and the European Research Council (grant agreement ID 101042183). The OSMR analyses have been conducted using the UK Biobank Resource under Application Number 22224.

Jan 20, 2024 | medrxiv.org | Shuyang Yao |Fahimeh Darki |Yu-Wei Chang |Arvid Harder

PFS is a scientific consultant and shareholder for Neumora Therapeutics. JHL was supported by the Swedish Research Council (award 2018-00799), Swedish Brain Foundation (award FO2018-0272) and European Research Council (SCHIZTYPE, grant agreement 819540). PFS was supported by the Swedish Research Council (award D0886501) and the US National Institute of Mental Health (R01s MH124871, MH121545, and MH123724).